louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04450459: Impact of Spiroergometer Parameters as Diagnostic Marker of Cardiac Ischemia in Pts. With Stable Angina Compared to FFR.
Official title: Impact of Ergospirometric Oxygen Uptake Under Exercise as Diagnostic Marker of Cardiac Ischemia in Patients With Stable Angina Compared to Non Invasive and Invasive (FFR) Measurement of Ischemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stable Angina
Keywords: FFR Measurement; exercise testing, ergospirometer
Lead sponsor: Jena University Hospital
Sponsor class: OTHER
First posted: 2020-06-29
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with suspected CAD presenting for diagnostic testing/ coronary angiography

Brief summary: In Patients with stable Angina pectoris CCS 1-3 exercise testing for ischemia detection is widely used despite the known limitations. Measurement of the FFR is invasive but gold standard for Ischemia detection.

Adding of parameters of spiroergometer might help to improve diagnostic accuracy of non invasive exercise testing. Therefore the trial is evaluating diagnostic accuracy of spiroergometric parameters compared to invasive FFR measurement.


Eligibility criteria: Inclusion Criteria:

* stable Angina (CCS \>1-3) with suspected CAD or
* dyspnoea at exertion NYHA \>2 or
* signs of ischemia within SPECT or exercise electrocardiography
* willingness to participate in the trial

Exclusion Criteria:

* Unstable angina or myocardial infarction within the last 2 weeks
* inability to perform bicycle exercise test
* significant valvular disease
* HOCM
* av- block \>I degree
* asthma bronchiales

Primary outcomes:
measure: double slope sign of ΔV̇O2/ΔWR-Increase
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Jena
country: Germany
facility: Universityhospital
Study officials:
affiliation: Universityhospital Jena
name: Sven Möbius-Winkler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06984159: The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Official title: An Open-Label, Single-Arm, Multicenter Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Advanced Prostate Cancer
Lead sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-05-22
Enrollment: 137
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer


Eligibility criteria: Inclusion Criteria:

* After having the scope and nature of the study explained, subjects must voluntarily sign the ICF prior to the screening visit and be willing to comply with the study requirements and cooperate with all scheduled tests
* Male, aged ≥ 18 years old.
* Pathologically confirmed advanced prostate cancer candidate for Androgen Deprivation Therapy, including patients those who have undergone radical treatment (surgical resection, external radiotherapy, or cryotherapy).

Exclusion Criteria:

* Received or are undergoing Androgen Deprivation Therapy (surgical castration or drug Androgen Deprivation Therapy including but not limited to gonadotropin-releasing hormone \[GnRH\] receptor agonists, GnRH receptor antagonists, estrogen and progesterone and their analogs, androgen receptor antagonists, androgen synthesis inhibitors, etc.).
* Major surgery (including but not limited to radical prostatectomy, etc.), radiotherapy, chemotherapy, immunotherapy, cryotherapy, etc. within 4 weeks prior to the screening visit, or plan to receive the above treatments during the study
* Receipt of any vaccination within 4 weeks prior to first dose (except COVID-19 vaccination).

Primary outcomes:
measure: Cumulative probability of maintaining serum testosterone at a castrate level (≤ 50 ng/dL) from the end of 28 days after the first dose to the end of 168 days after the second dose.
timeFrame: from the end of 28 days after the first dose to the end of 168 days after the second dose.
measure: including but not limited to:adverse events (AEs) and serious adverse events (SAEs), vital signs, physical examination, laboratory tests, 12-lead electrocardiogram (ECG), injection site reactions, local tolerance, etc.
timeFrame: 336 days
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
state: Guangdong
Study officials:
References:
Clinical trial NCT06399159: Prediction of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma Based on Ultrasound and Cytological Images
Official title: An Interpretable Multimodal Model Based on Cytology Ultrasound Noninvasively Predicts Lymph Node Metastasis in cN0 Papillary Thyroid Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Papillary Thyroid Carcinoma
Lymph Node Metastasis
Keywords: ultrasound
deep learning
cytology
Lead sponsor: Nanchong Central Hospital
Sponsor class: OTHER_GOV
First posted: 2024-05-03
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with papillary thyroid cancer from ten hospitals in China

Brief summary: Rising thyroid carcinoma rates, with papillary thyroid carcinoma (PTC) as the main type (85-90% of cases), often show early cervical lymph node spread. This increases the risk of PTC patients for recurrence and death. A new study's multimodal model fuses preoperative US and cytology images to better predict lymph node metastasis, aiming to improve treatment plans, reduce unnecessary surgeries, and enhance patient outcomes.

Detailed description: Thyroid carcinoma incidence has been on the rise in recent years. Papillary thyroid carcinoma is the most prevalent type of differentiated thyroid carcinoma, accounting for 85% to 90% of malignant thyroid tumors. Despite its indolent nature, cervical lymph node metastasis is frequently observed at an early stage. Papillary thyroid carcinoma patients with cervical lymph node metastasis face an elevated risk of recurrence, distant metastasis, and mortality. Thus, non-invasive preoperative prediction of cervical lymph node metastasis is particularly vital for guiding treatment plans and prognostic. this study has developed a multimodal model integrating preoperative US images with cytological images of papillary thyroid carcinoma patients. The aim is to enhance the predictive accuracy for cervical lymph node metastasis, reduce unnecessary lymph node dissections, and provide real-time, precise guidance for determining the extent of surgical resection and prognostic assessment. This approach aims to optimize patient treatment strategies and enhance therapeutic outcomes.

Eligibility criteria: Inclusion Criteria:

* Underwent thyroidectomy and bilateral lymph node dissection with pathological confirmation of PTC
* Completed US examination within one week before surgery
* Underwent preoperative us-guided FNAC
* Completed cytological images at 400× magnification under a microscope

Exclusion Criteria:

* Patients who underwent only unilateral thyroidectomy
* Patients with cervical lymph nodes shown on preoperative ultrasound

Primary outcomes:
measure: Presence or absence of lymph node metastasis
timeFrame: October 2024
Secondary outcomes:
Other outcomes:
Locations:
city: Nanchong
country: China
facility: Nanchong central hospital
state: Sichuan
Study officials:
affiliation: Nanchong Central Hospital
name: Xiachuan Qin, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02756559: MiRNAs Evaluating Lymphocyte Proliferation and Apoptosis as Well as Prognosis of Sepsis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: T Lymphocyte Disorder
Keywords: sepsis
microRNAs
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2016-04-29
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Blood samples were collected from the Chinese People's Liberation Army General Hospital. The investigators collected samples in emergency intensive care unit (EICU), surgical intensive care unit (SICU) and respiratory intensive care unit (RICU),within 24 hours admitted into ICU.

Brief summary: Sepsis is a systemic inflammatory reaction caused by infection, trauma, etc. In the process of sepsis, the apoptosis of lymphocyte serves as a vital factor of immune dysfunction. Micro-RNAs (miRNAs) are endogenous small non-coding RNA molecules. Our previous studies have showed the diagnostic and prognostic value of a series circulant miRNAs in human serum in sepsis. The present research further study the regulatory mechanism of those miRNAs in lymphocyte in sepsis. Our research is based on the clinical value of miR-223, miR-15a, miR-16. The investigators discuss the potential role of miR-223, miR-15a, miR-16 in regulating the proliferation and apoptosis of lymphocyte in sepsis and aim to find new targets for sepsis treatment.

Detailed description: Blood samples were collected from the Chinese People's Liberation Army General Hospital. The investigators collected samples in emergency intensive care unit (EICU), surgical intensive care unit (SICU) and respiratory intensive care unit (RICU) between July 2014 to March 2015. Septic patients were divided into sepsis, severe sepsis and septic shock according to the diagnostic criteria. Peripheral white blood cells were sorted into monocytes, lymphocytes and neutrophils by using flow cytometry (Flow Cytometry, FCM). Jurkat T cell lines were purchased from Chinese Academy of Medical Sciences Institute of basic medical sciences. miRNAs agomirs and antagonists were used to establish miR-223, miR-15a, miR-16 overexpression and knock-out transient transfection cell lines. Western blot was used to detect difference expression of protein expression.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Sepsis
* Agree with this study

Exclusion Criteria:

* Age \<18 years
* Died within 24 hours
* Combined with HIV infection
* Agranulocytosis

Primary outcomes:
measure: all cause mortality
timeFrame: 28 days after admitted to ICU
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese People's Liberation Army General Hospital
state: Beijing
Study officials:
affiliation: Chinese PLA General Hospital
name: Lixin Xie, Clinical Professor
role: STUDY_CHAIR
References:
Clinical trial NCT00725959: Online Social Networking for HIV Prevention
Official title: Online Social Networking for HIV Prevention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV
Keywords: HIV Prevention
Social Networking
Technology Based Intervention
Lead sponsor: Colorado School of Public Health
Sponsor class: OTHER
Collaborators: name: National Institute of Nursing Research (NINR)
name: Internet Sexuality Information Services (ISIS)
name: Columbia University
name: Rutgers University
First posted: 2008-07-31
Enrollment: 1578
Sex: ALL
Minimum age (years): 16
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this randomized controlled trial, we will identify social networks on Facebook, an randomly assign each network to control or intervention status. We will then intervene at the level of the network with dynamic, interactive HIV prevention messages (intervention) or static messages about HIV prevention (control). We will develop the intervention content with input from our target audience (Facebook users) and will measure baseline, and 3 and 6 month assessments of condom use and abstinence among all participants


Eligibility criteria: Inclusion Criteria:

* Facebook user with an existing Facebook page
* at least 16
* no older than 24
* English speaker

Exclusion Criteria:

* older than 24 or younger than 16
* non English speaker
* does not have a Facebook page

Primary outcomes:
measure: Proportion of Condom Usage
timeFrame: two months
Secondary outcomes:
measure: Condom and Abstinence Norms, Attitudes, Self-efficacy and Intentions
timeFrame: two months
Other outcomes:
Locations:
Study officials:
affiliation: University of Colorado at Denver and Health Sciences
name: Sheana Bull, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bull SS, Levine DK, Black SR, Schmiege SJ, Santelli J. Social media-delivered sexual health intervention: a cluster randomized controlled trial. Am J Prev Med. 2012 Nov;43(5):467-74. doi: 10.1016/j.amepre.2012.07.022.
Clinical trial NCT01888159: Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ovarian Cancer
Lead sponsor: Karlstad Central Hospital
Sponsor class: OTHER
First posted: 2013-06-27
Enrollment: 100
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Randomised study to investigate if salpingectomies done to women wishing tubal sterilisation has an effect on ovarian reserve.


Eligibility criteria: Inclusion Criteria:

* Women seeking for tubal sterilisation

Exclusion Criteria:

* women older than 45
* family history of ovarian cancer
* presence of menopausal symptoms
* irregular cycles
* Hormone Replacement Therapy or hormone contraceptions the last 3 months
* history of previous ovarian or uterine surgeries
* imaging suggesting an ovarian cyst or other adnexal pathology during investigation
* previous salpingectomy

Primary outcomes:
measure: Anti-Mullerian hormone (AMH)and Follicle Stimulation Hormone (FSH)
timeFrame: 3 months
Secondary outcomes:
measure: Anti-Mullerian hormone (AMH)
timeFrame: 1 year
measure: Operative time
timeFrame: Postoperatively
measure: Complications
timeFrame: 3 months
Other outcomes:
measure: Follicle Stimulation Hormone (FSH)
timeFrame: 3 months
measure: Follicle Stimulation Hormone (FSH)
timeFrame: 1 year
Locations:
city: Karlstad
country: Sweden
facility: Department of Obstetrics and Gynecology
state: Värmaland
Study officials:
References:
Clinical trial NCT06620159: Lymphocyte to Procalcitonin Ratio in Covid-19 Patients
Official title: Lymphocyte to Procalcitonin Ratio: A New Predictor of Prognosis and Mortality in Covid
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: COVID-19
Lead sponsor: Suleyman Demirel University
Sponsor class: OTHER
First posted: 2024-10-01
Enrollment: 535
Sex: ALL
Minimum age (years): 23
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients over 18 years of age who applied to suleyman demirel university emergency department and diagnosed with covid 19 by PCR

Brief summary: The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

Detailed description: The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. The auc value, PPV and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/CRP ratio.

Eligibility criteria: Inclusion Criteria:

* Covid19 PCR test positive

Exclusion Criteria:

* Pregnancy Under 18 years old

Primary outcomes:
measure: outcome
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Isparta
country: Turkey
facility: Süleyman demirel üniversitesi tıp fakültesi
Study officials:
affiliation: suleyman demirel university faculty of medicine
name: Furkan Ç Oğuzlar, asst. prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00546559: Differential Metabolic Effects of Statins
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Keywords: Lipophilic statins
Insulin resistance
simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2007-10-19
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE

Brief summary: The investigators hypothesized simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.


Eligibility criteria: Inclusion Criteria:

* Low-density lipoprotein cholesterol levels \> 130

Exclusion Criteria:

* Overt liver disease,
* Chronic renal failure
* Hypothyroidism
* Myopathy
* Uncontrolled diabetes
* Severe hypertension

Primary outcomes:
measure: Simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
Secondary outcomes:
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Gil Medical Center
Study officials:
affiliation: Gachon University Gil Medical Center
name: Kwang K Koh, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13. doi: 10.1038/sj.bjp.0702397.
Clinical trial NCT03992859: Continuous Serrates Plane Block in Axillary Dissection
Official title: Continuous Serratus Plane Block Added to PECS II vs PECS II Alone for Post Operative Analgesia After Axillary Dissection in Breast Cancer Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Cancer
Keywords: regional anesthesia
Lead sponsor: Azienda USL Reggio Emilia - IRCCS
Sponsor class: OTHER_GOV
First posted: 2019-06-20
Enrollment: 84
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients undergone to axillary dissection during breast surgery with a PECS I, II block will be randomized to receive either a serratus plane continuous local anesthetic infusion through a multiple hole catheter or nothing. Both groups will receive a patient controlled analgesia with morphine.

Detailed description: 84 patients ASA I-III undergoing breast surgery with axillary dissection after modified PECS II block as described by Blanco et al. with Ropivacaine 0.37% 30 ml. General anesthesia with remifentanil 0.1 mcg/Kg/min and Propofol 1.5-2 mg/Kg to facilitate endotracheal intubation will provide for all patients, and maintained with Desflurane and Remifentanil infusion. In case of axillary dissection patient will be randomized to receive either a serratus plane continuous local anesthetic infusion through a multiple hole catheter or nothing. Both groups will receive as intraoperative analgesia 1 g Acetaminophene ev 30 minute before the end of the surgery and 1g. 8h-1 postoperative associated to a patient controlled analgesia with morphine. PCA will set up as follow: bolus 1 mg, lock-out 6 minute, max 20 mg/4h. In the serratus group 10 ml of Ropivacaine 0.5% before fascial closure and a continuous infusion of 12 ml/h of Ropivacaine 0.2% will be provide.

Eligibility criteria: Inclusion Criteria:

* age \> 18
* breast surgery
* informed consent

Exclusion Criteria:

* ASA \>3
* allergy to local anesthetic
* opioid administration in the last month
* patient refusal

Primary outcomes:
measure: Morphine consumption
timeFrame: 12-48 hours
Secondary outcomes:
measure: persistent post-surgical pain: numerical rating scale
timeFrame: 3-6 months
Other outcomes:
Locations:
city: Reggio Emilia
country: Italy
facility: Ausl-Irccs Reggio Emilia
state: RE
Study officials:
affiliation: Azienda USL Reggio Emilia - IRCCS
name: Federico bizzarri, MD
role: PRINCIPAL_INVESTIGATOR
References: